HIF1A and Miyoshi myopathy: In a MM xenograft mouse model, the deubiquitinase TRIM44 promotes the quiescence of stem cancer cells; on the other hand, TRIM44 can spur the proliferation and survival of MM cells under hypoxia via elevating the expression level of HIF-1α, which ultimately exerts a drug-resistant and oncogenic effect.135